Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lee's Pharm In-Licenses Asia Rights to RDS Treatment in $40 Million Deal

publication date: Jun 16, 2017
Lee's Pharm of Hong Kong will develop and market KL4 surfactant therapies for respiratory diseases, primarily for infants, in select Asian countries for Windtree Therapeutics of the US. Anticipating the agreement, Lee's previously invested $2 million in Windtree's private placement, and it will pay a $1 million upfront fee. The agreement also includes $37.5 million in potential milestones, plus royalties. Lee's will be responsible for development in the territories, and it has the right to manufacture non-aerosol KL4 surfactant for use in Asia. More details....

Stock Symbols: (HK: 0950) (OTCQB: WINT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital